Kronos Bio Inc
Change company Symbol lookup
Select an option...
KRON Kronos Bio Inc
NVSAW New Vista Acquisition Corp *W EXP 02/01/2026
$R25IGTRI Russell 2500 Growth TR Index
QQQ Invesco QQQ Trust
PRDO Perdoceo Education Corp
DITHF DS Smith PLC
BIOL BIOLASE Inc
GOEV Canoo Inc
CHE Chemed Corp
ASTA WorldFlix Inc
Go

Health Care : Biotechnology |
Company profile

Kronos Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of cancer therapeutics designed to target dysregulated transcription. Its product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks (TRNs) that drive their oncogenic activity. Its lead product candidate, entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase (SYK) inhibitor that is being developed for the treatment of acute myeloid leukemia (AML). Its second product candidate, KB-0742, is generated from its product engine’s small molecule microarray (SMM) platform. KB-0742 is designed to be an orally bioavailable inhibitor of CDK9 with a differentiated selectivity profile. Its KB-0742 is in advanced solid tumors with MYC genomic copy number gain (amplification).

Closing Price
$16.78
Day's Change
0.36 (2.19%)
Bid
--
Ask
--
B/A Size
--
Day's High
17.04
Day's Low
16.10
Volume
(Average)
Volume:
215,180

10-day average volume:
235,559
215,180

GM stock rallies after Engine No. 1 announces investment on CNBC

9:26 am ET October 4, 2021 (MarketWatch)
Print

Shares of General Motors Co. (GM) rallied 3.3% in premarket trading Monday, after hedge fund Engine No. 1 said on CNBC that it has invested in the automaker as it supported GM's move into electrification. The rally puts the stock on track to open at the highest level seen during regular-session hours since Aug. 12. Engine No. 1 founder Chris James said on CNBC that he believes given GM's approach to go "all in" to transition to battery electric vehicles (BEV), "we think they can be successful in this transition." Engine No. 1 was an activist investor in Exxon Mobil Corp. (XOM), and James said the same the beliefs that led to an investment in Exxon Mobil, which is going through a transition, led to an investment in GM. GM's stock has lost 9.9% over the past three months through Friday, while shares of rival Ford Motor Co. (F) have lost 5.2%, electric vehicle giant Tesla Inc. (TSLA) have rallied 14.2% and the S&P 500 has ticked up 0.1%.

-Tomi Kilgore

	

(END) Dow Jones Newswires

October 04, 2021 09:26 ET (13:26 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.